Withus Pharmaceutical.

At a glance

Withus Pharmaceutical. filed 12 disclosures in the last 12 months, including 1 buyback. The most recent key filing was on Mar 6.

Revenue for 2025 was ₩106B, up 3.6% on 2024. Operating margin was 5.3% against 5.5% a year earlier. Debt was 39% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩57.3B and operating profit of ₩1.3B.

The 2025 annual report lists 220 employees with an average tenure of 6.7 years and average pay of ₩52.8M, #1322 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩183.4M each on average. It paid no cash dividend for 2025. 성대영 and related parties held 52.98% at year end.

From the 2025 annual report

Staff: 220 (127 men, 93 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩11.6B. Directors and auditors: 5, paid ₩916.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

성대영 holds 52.47%; with 2 related parties the group holds 52.98% of common shares at year end.

Auditor: 대현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary